Año 2024 / Volumen 116 / Número 9
Original
FIB-4 score as a predictor of COVID-19-related severity in hospitalized patients

465-471

DOI: 10.17235/reed.2024.9811/2023

Ana Lucena Valera, Rocío Aller de la Fuente, Yolanda Sánchez Torrijos, Manuel Romero Gómez, Javier Ampuero Herrojo,

Resumen
Aim: to determine the impact of liver fibrosis on the prognosis of COVID and liver injury associated with the infection. Methods: retrospective multicenter study including 575 patients requiring admission for COVID-19 between January and June 2020. Fibrosis index-4 (FIB-4) was calculated within six months prior to infection and at six months post-infection. Results: baseline FIB-4 was elevated in patients who died (1.91 ± 0.95 vs 1.43 ± 0.85; p < 0.001). In addition, 17.1 % (32/187) of patients with baseline FIB-4 < 1.45 died vs 52.9 % (9/17) with FIB-4 > 3.25 (p < 0.001). In the adjusted multivariate analysis, baseline FIB-4 (OR 1.61 [95 % CI: 1.19-2.18]; p = 0.002) was independently associated with mortality. Parameters associated with liver injury, including aspartate aminotransferase (AST) (28 ± 10 vs 45 ± 56 IU/l; p < 0.001) and alanine aminotransferase (ALT) (20 ± 12 vs 38 ± 48 IU/l; p < 0.001) were significantly higher at admission compared to baseline. Furthermore, FIB-4 increased from baseline to the time of admission (1.53 ± 0.88 vs 2.55 ± 1.91; p < 0.001), and up to 6.9 % (10/145) of patients with FIB-4 < 1.45 on admission died vs 47.5 % if FIB-4 > 3.25 (58/122) (p < 0.001). In the adjusted multivariate analysis, FIB-4 on admission (OR 1.14 [95 % CI: 1.03-1.27]; p = 0.015) was independently associated with mortality. In addition, AST (42 ± 38 vs 22 ± 17 IU/l; p < 0.001) and ALT (40 ± 50 vs 20 ± 19 IU/l; p < 0.001) were significantly reduced at six months after the resolution of infection. Accordingly, FIB-4 decreased significantly (2.12 ± 1.25 vs 1.32 ± 0.57; p < 0.001) six months after the infection. Conclusion: increased FIB-4, either at baseline or at the time of admission, was associated with severity and mortality related to respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the liver damage expressed by elevated transaminases and FIB-4 levels was reversible in most of patients.
Resumen coloquial
The prevalence of abnormal liver function tests in COVID-19 patients has been reported to range from 15% to 70%. In this setting, liver fibrosis could be a relevant factor in the natural history of COVID-19. FIB-4 is a simple four-variable tool (including AST, ALT, age, and platelet) for estimating liver fibrosis. In our study, we observed that patients with increased FIB-4 had a higher severity and mortality related to SARS-CoV-2 infection. The early identification of high-risk patients could improve patient care and prognosis of SARS-CoV-2 infection.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Gato S, Lucena-Valera A, Muñoz-Hernández R, et al. Impact of COVID-19 on liver disease: From the experimental to the clinic perspective. World J Virol. 2021;10(6):301-311.
2. Bloom PP, Meyerowitz EA, Reinus Z, et al. Liver Biochemistries in Hospitalized Patients With COVID-19. Hepatology. 202173(3):890-900.
3. Hundt MA, Deng Y, Ciarleglio MM, et al. Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. Hepatology. 2020;72(4):1169-1176.
4. Ampuero J, Romero Gómez M. COVID-19 and the liver: the chicken or the egg dilemma. Rev Esp Enferm Dig. 2021;113(7):555.
5. Ampuero J, Lucena A, Hernández-Guerra M, et al. Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes. Gut. 2021; 7:gutjnl-2021-325700.
6. Sterling RK, Lissen E, Clumeck N, el at. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-25.
7. Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Journal of Hepatology. 2018;68(2):305-15.
8. Crisan D, Avram L, Grapa C, et al. Liver Injury and Elevated FIB-4 Define a High-Risk Group in Patients with COVID-19. J Clin Med. 2021 28;11(1):153.
9. Li Y, Regan J, Fajnzylber J, Coxen K, et al. Liver Fibrosis Index FIB-4 Is Associated With Mortality in COVID-19. Hepatol Commun. 2021;5(3):434-445.
10. Pranata R, Yonas E, Huang I, et al. Fibrosis-4 index and mortality in coronavirus disease 2019: a meta-analysis. Eur J Gastroenterol Hepatol. 2021; 1;33(S1):368-374.
11. Ibáñez-Samaniego L, Bighelli F, Usón C, et al. Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19. J Infect Dis. 2020; 222(5):726-733.
12. APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640), Sarin SK, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int; 2020;14(5):690-700.
13. Wang Y, Hu M, Yang H. Cirrhosis is an independent predictor for COVID-19 mortality: A meta-analysis of confounding cofactors-controlled data. J Hepatol. 2023;78(1):28-31
14. Bertolini A, van de Peppel IP, Bodewes F, et al. Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. Hepatology. 2020;72(5):1864-1872.
15. Levin AT, Hanage WP, Owusu-Boaitey N, et al. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Epidemiol. 2020;35(12):1123-1138.
16. Chen LY, Chu HK, Bai T, et al. Liver damage at admission is an independent prognostic factor for COVID-19. J Dig Dis 2020;21:512-518.
17. Ampuero J, Sánchez-Torrijos Y, García Lozano MR, et al. Impact of liver injury on the severity of COVID-19: Systematic Review with Meta-analysis. Rev Esp Enferm Dig. 2020; 113(2):125-135.
18. Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect. 2020;80(6):656-665.
19. Canillas L, Broquetas T, Carrión JA, et al. Follow-up evaluation of patients with liver test abnormalities detected during SARS-CoV2 infection. J Viral Hepat. 2022;29(9):823-834.
Artículos relacionados

Carta

Autoimmune hepatitis after SARS-C¬¬oV-2 vaccination

DOI: 10.17235/reed.2023.9579/2023

Imagen en Patología Digestiva

Colangiopatía post-COVID: hallazgos ultrasonográficos y de CPRE

DOI: 10.17235/reed.2022.9218/2022

Imagen en Patología Digestiva

Acute respiratory failure secondary to megaesophagus: think beyond COVID-19

DOI: 10.17235/reed.2022.8847/2022

Carta

COVID-19 vaccine and autoimmune hepatitis

DOI: 10.17235/reed.2022.8837/2022

Carta

Abdomen agudo quirúrgico y vacunación de COVID-19

DOI: 10.17235/reed.2022.8721/2022

Carta

Hepatitis AMA positivo inducida por la vacuna contra SARS-CoV-2

DOI: 10.17235/reed.2022.8533/2021

Carta

A case of COVID-19 with concomitant infection with hepatitis A

DOI: 10.17235/reed.2021.8372/2021

Carta

COVID-19 and aorto-enteric fistula

DOI: 10.17235/reed.2021.8272/2021

Imagen en Patología Digestiva

Trombosis portal en un paciente con infección por SARS-CoV-2

DOI: 10.17235/reed.2021.8099/2021

Carta

Hepatitis autoinmune desencadenada por la COVID-19

DOI: 10.17235/reed.2021.8045/2021

Carta

Neumoperitoneo y COVID-19. ¿Una asociación causal?

DOI: 10.17235/reed.2021.7877/2021

Carta

COVID-19 and the liver: the chicken or the egg dilemma

DOI: 10.17235/reed.2021.7861/2021

Carta

Daño pancreático: pancreatitis aguda en pacientes COVID-19

DOI: 10.17235/reed.2021.7807/2021

Editorial

Gobernar en tiempos turbulentos con afán de servir

DOI: 10.17235/reed.2020.7684/2020

Carta

Pancreatic injury in COVID-19: pathogenesis and challenges

DOI: 10.17235/reed.2020.7541/2020

Carta

SARS-CoV-2 and acute pancreatitis: a new etiological agent?

DOI: 10.17235/reed.2020.7481/2020

Carta

COVID-19. Immunothrombosis and the gastrointestinal tract

DOI: 10.17235/reed.2020.7292/2020

Carta

Efecto del Adacolumn® en colitis ulcerosa con COVID-19

DOI: 10.17235/reed.2020.7156/2020

Revisiones Rápidas

COVID-19, coronavirus, SARS-CoV-2 and the small bowel

DOI: 10.17235/reed.2020.7137/2020

Instrucciones para citar
Lucena Valera A, Aller de la Fuente R, Sánchez Torrijos Y, Romero Gómez M, Ampuero Herrojo J. FIB-4 score as a predictor of COVID-19-related severity in hospitalized patients. 9811/2023


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 578 veces.
Este artículo ha sido descargado 49 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 30/06/2023

Aceptado: 26/04/2024

Prepublicado: 20/05/2024

Publicado: 09/09/2024

Tiempo de revisión del artículo: 285 días

Tiempo de prepublicación: 325 días

Tiempo de edición del artículo: 437 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas